# Cholesterol Lowering and Residual Risk in Diabetes, Type 1

Study · id `cardio:ct-nct05641753` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05641753](<https://clinicaltrials.gov/study/NCT05641753>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05641753

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 125 participants.

## Technical summary

Registry record NCT05641753. Allocation not applicable; no masking; primary purpose other. Start 2022-12-06 (actual); primary completion 2027-07-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose other
- Phase: Phase 4
- Enrolled: 125 participants (planned count; ClinicalTrials.gov record NCT05641753, source copy `cardio:ctgov-nct05641753-2026-10-28`, retrieved 2026-10-31)
- Started: 2022-12-06 (actual) (ClinicalTrials.gov record NCT05641753, source copy `cardio:ctgov-nct05641753-2026-10-28`, retrieved 2026-10-31)
- Primary completion: 2027-07-01 (anticipated) (ClinicalTrials.gov record NCT05641753, source copy `cardio:ctgov-nct05641753-2026-10-28`, retrieved 2026-10-31)
- Completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT05641753, source copy `cardio:ctgov-nct05641753-2026-10-28`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT05641753, source copy `cardio:ctgov-nct05641753-2026-10-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05641753-2026-10-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: Cholesterol Lowering and Residual Risk in Diabetes, Type 1
- Acronym: CHORD1
- Condition: Type 1 Diabetes
- Intervention (Drug): Evolocumab Cartridge
- Intervention (Drug): Atorvastatin Calcium Tablets
- Intervention (Drug): Ezetimibe Tablets
- Intervention (Drug): 18F-FDG
- Intervention (Device): Angiocatheter 20IV
- Intervention (Device): J-Wire
- Intervention (Device): GlycoCheck Glycocalyx Measurement Software
- Lead sponsor: NYU Langone Health
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Type 1 diabetes (`core:type-1-diabetes`)
- Registry lists this organization as the lead sponsor: NYU Langone Health (`cardio:org-nyu-langone-health`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: 9a11ede16340a941c230403659a54caa0e44afa56a4143939245f7a402ebd5e8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
